Enliven announces $90M private placement financing

Enliven Therapeutics “announced that it has entered into a securities purchase agreement for a private investment in public equity, or PIPE, financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.”